

Risk Based Approach for the Management of T2D Webinar



You are invited to attend an expert-led panel meeting to discuss the importance of a risk based approach to managing people with type 2 diabetes and the interrelated complications.



When: Wednesday, 26th May 2021



Time: 7:30 pm - 9:00 pm AEST

Chairperson:



Dr Kean-Seng Lim

MBBS (SYD), FRACGP, FAMA, GAICD
Australian Medical Association (AMA) NSW
President & GP at Mt Druitt Medical Centre.

Faculty:



Dr Brendan McQuillan

MB BS PhD W.Aust., FRACP, Cardiologist
and Director of Echocardiography at Sir
Charles Gairdner Hospital (SCGH), Dean
and Head of the Medical School at the
University of WA.



Professor Michael d'Emden

Director of the Department of Endocrinology
and Diabetes, Royal Brisbane and Women's
Hospital (RBWH), a Clinical Associate
Professor of the University of Queensland
and previous Vice President of the
Australian Diabetes Society.



Dr Gary Deed

MBBS FACNEM MRACGP, Chair of the
Diabetes Specific Interest Network RACGP
and General Practitioner, Coorparoo, QLD.

Agenda:


TIME	TOPIC	SPEAKER
7:30 pm	Welcome & Introduction	Dr Kean-Seng Lim
7:35 pm	Risk based approach for the management of T2D	Dr Gary Deed
7:50 pm	Prevention of Hospitalisation for Heart Failure in T2D	Prof Michael d'Emden
8:05 pm	Treatment of Symptomatic Heart Failure in people with or without T2D	Dr Brendan McQuillan
8:20 pm	Panel Discussion – Q & A	Panel
9:00 pm	Wrap Up & Close	Dr Kean-Seng Lim

To Register, please Scan



OR

[Click Here for Registration](#)



Risk Based Approach for the Management of T2D Webinar


forxiga
(dapagliflozin)

BEFORE PRESCRIBING PLEASE REVIEW FULL PRODUCT INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA ON 1800 805 342 OR www.astrazeneca.com.au/PI

PBS Information: FORXIGA: Authority required (STREAMLINED). Type 2 Diabetes. Refer to PBS Schedule for full Authority Required Information. This product is not listed on the PBS for the treatment of heart failure.

This webcast has been initiated, organised and funded by AstraZeneca. The content is intended for registered HealthCare Professionals for educational purposes. The company seeks no commitment from external stakeholders to take any action as a result of the invitation or related support.

PRIVACY STATEMENT: Your personal information ("Information") will be collected and used by AstraZeneca Pty. Ltd. ("AstraZeneca") for the purpose of administration of this webcast, for follow-up purposes and for any other purpose described in AstraZeneca's Privacy Policy (see below for link).

AstraZeneca may disclose your Information to third parties such as our related entities or service providers (including IT support/service providers), some of which may be located overseas including in the US, European Union and Asia Pacific. Please refer to our Privacy Policy (<https://www.astrazeneca.com.au/privacy-policy.html>) for more information about how your Information is handled and how you may seek to access or correct your Information, or submit a privacy complaint.

AstraZeneca 

FORXIGA® is a registered trademark of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via <https://contactazmedical.astrazeneca.com> or email Medical Information enquiries to medinfo.australia@astrazeneca.com. AU-10417, E-011406, April 2021